Difference between revisions of "Post-transplant lymphoproliferative disorder"

From Libre Pathology
Jump to navigation Jump to search
m (fix typo)
 
(2 intermediate revisions by the same user not shown)
Line 18: Line 18:
==IHC==
==IHC==
*B cell markers +ve.
*B cell markers +ve.
*EBER diffusely +ve.
*[[EBER]] diffusely +ve.


==See also==
==See also==
Line 24: Line 24:
*[[Heart transplant pathology]].
*[[Heart transplant pathology]].
*[[Lung transplant pathology]].
*[[Lung transplant pathology]].
*[[Lymphoproliferative disorder]].


==References==
==References==
{{Reflist|1}}
{{Reflist|2}}


[[Category:Haematopathology]]
[[Category:Haematopathology]]
[[Category:Diagnosis]]

Latest revision as of 19:56, 26 December 2019

Post-transplant lymphoproliferative disorder, abbreviated PTLD, is something afflicts people that had transplants (solid organ and bone marrow). It is essentially a type of B-cell lymphoma.

General

  • Rare.
  • B cell neoplasm associated with EBV.[1][2]
    • May develop from a clinically latent EBV infection that is detectable by the presence of "passenger cells" = scattered EBER positive lymphocytes.[3]
  • Commonly in the GI tract as it gets the most immunosuppression; immunosuppressives are taken orally -- not cleaned by the liver prior to reaching the GI tract.

Microscopic

Features:

  • Similar to large cell lymphomas:
    • Large lymphoid cells with a diameter ~2x a resting lymphocyte.
    • Nucleoli.

DDx:

IHC

  • B cell markers +ve.
  • EBER diffusely +ve.

See also

References

  1. URL: http://emedicine.medscape.com/article/431364-overview. Accessed on: 10 February 2011.
  2. Gottschalk S, Rooney CM, Heslop HE (2005). "Post-transplant lymphoproliferative disorders". Annu. Rev. Med. 56: 29–44. doi:10.1146/annurev.med.56.082103.104727. PMID 15660500.
  3. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/. Accessed on: 3 March 2011.